Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review

Cancer-associated thrombosis (CAT) is a devastating complication of cancer that can significantly impact a patient’s health and life. The incidence of CAT is approximately 20%, and 1 in 5 cancer patients will develop CAT annually. Indeed, CAT can promote pulmonary embolism and deep vein thrombosis,...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Agnese Maria Fioretti, Tiziana Leopizzi, Daniele La Forgia, Raffaele De Luca, Donato Oreste, Riccardo Inchingolo, Pietro Scicchitano, Stefano Oliva
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	IMR Press 2023-10-01
Σειρά:	Reviews in Cardiovascular Medicine
Θέματα:	cancer-associated thrombosis factor xi inhibitors abelacimab bleeding risk
Διαθέσιμο Online:	https://www.imrpress.com/journal/RCM/24/10/10.31083/j.rcm2410295
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!